Hesk: I see this work by researchers at University of Melbourne, as validating a 'proof of concept' in the use of a phylomer to target this pathway with a unique mechanism. By publishing the article, academics and pharma scientists are made aware of the value Phylomers have in this area.
IMO the Endosomal Escape Trap and accompanying technologies are the main ball game. I would expect any validated 'proof of concept' from the universities (Cambridge, Melbourne and Queensland) would hopefully build additional value, if & when M&A comes.
SoT
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.035(2.70%) |
Mkt cap ! $734.9M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.26 | $2.681M | 2.075M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3081 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 700 | 1 |
View Market Depth
| Last trade - 16.11pm 28/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |